Dr. Dan Safarpour received a B.S. in Chemistry in 1991 from the University of Arkansas, Fayetteville and a Ph.D. in Environmental Analytical Chemistry in 2001 from Rutgers University, Cook College, New Brunswick, New Jersey. Dr. Dan Safarpour started his professional career as residue chemist atAltheimer Laboratory of the University of Arkansas in Fayetteville, Arkansas. In 1993, he began employment with American Cyanamid Company, Princeton, New Jersey as an Analytical Chemist in the Toxicology Analysis laboratory. Later, within Cyanamid Global Research Center, he moved to other research group called Metabolism, Residue, Environmental Fate and Eco-Toxicology (MREE) Group as a Residue Chemist/Study Director. In 2000, American Cyanamid Company was acquired by BASF Corporation, at which time he joined the Formulations Analysis Group. In September 2001, he joined Taxolog, Inc, a pharmaceutical/biotechnology startup company. As a group leader at Taxolog, he was brought on-board to build an analytical group capable of conducting formulations analysis support as well as metabolism and bioanalytical to determine metabolite structures to protect company IP on pharmaceutically active metabolites and co-drugs. Dr. Safarpour led his team in compiling analytical R&D and dossier preparation for filing several IND, CTX and aNDA in partnership with Pfizer corporation. Dr. Safarpour has been published in journals such as Journal of Pharmaceutical and Biomedical Analysis (JPBA), Journal of Chromatography, Electrophoresis, Journal of Associations of Officials in Analytical Chemistry (JAOAC) and Journal of Pesticide Science. Per invitation from US-EPA regulatory bodies, Dr. Safarpour has contributed a chapter on Application of Capillary Electrophoresis to Pesticide Analysis to the Encyclopedia of Agrochemicals. Dr. Safarpour has given numerous oral presentations in national and international conferences in the areas of separation sciences, process and formulations analysis, human and plant metabolism, bioanalytical, and residue chemistry. His presentations have focused on the use of cutting-edge technologies such as UPLC, HPLC, CE, and GC, as well as UPLC-MS-QTOF, HPLC-MS-Triple Quad platforms and CE-MS. Dr. Safarpour has chaired symposium in peptide-protein friendly instrumentations arena, judged poster presentations at ACS functions such as the Triangle Chromatography Discussion Group (TCDG). Since 2003 until 2015, Dr. Safarpour has served on the peer review committee for prestigious journals such as JPBA, JAOAC and Electrophoresis. In early 2009, Dr. Safarpour, with former colleagues, employees founded a new life sciences contract research organization called Symbiotic Research, LLC. In 2017, he sold Symbiotic Research to a German conglomerate-Tentamus GmbH. In 2018, together with Tentamus GmbH, Dr. Safarpour acquired animal research facility Genesis Midwest, LLC out of Wisconsin USA to enable Symbiotic Research to provide in-life and analytical package study services to its global Animal Health and Agrochemical clients. In 2014, Dr. Safarpour was hired by International Atomic Energy Agency (IAEA) Food Safety division as an “Expert Lecturer” to consult the agency by traveling to developing countries and guiding the subject nations on matters related to building laboratories and laboratory infrastructures capable of analyzing agricultural food products by LCMS and ultimately helping those nations to be able to export their raw agricultural products globally in an attempt to expand their GDP growth and aid in global food sustainability.

Dr. Martins-Green is Professor of Cell Biology in the Department of Molecular, Cell and Systems Biology at the University of California, Riverside. She came to the US from Portugal on a Fulbright Fellowship and received a PhD in Zoology with emphasis in Developmental Biology from the UCD Dec 1987. She then held a postdoctoral fellowship at the LBNL and then received a 3-year NRSA from NCI, and was Adjunct Assistant Professor at Rockefeller University before joining the UC Riverside faculty in 1993-present. Research: Professor Martins-Green is an internationally known researcher in the field of response to injury (including injury caused by tobacco toxins), wound healing and tissue engineering and pioneered the role of chemokines in wound healing and angiogenesis. She has also developed a murine model of chronic wounds to study of the basic cell and molecular mechanisms of chronic wound initiation and development. Her research has been funded by NCI, NIGMS, NAIAD, AHA and TRDRP and she has served on review panels for several agencies, including NIH, DOD and AHA. More on the research in the Biosketch. Honors/Awards Highlights: In addition to her Fulbright Fellowship for PhD studies in the US, her honors include Postdoctoral NRSA 1989-1991, other significant honors and awards include Member of the Standing Committee on Women in Cell Biology of the American Society for Cell Biology (2001-2006) and of the Advisory Board for the California Tissue Engineering Meeting and of TERMIS. Associate Editor of several journals through the years. She was Chair of the UCR Academic Senate (President of the Faculty) 2004-2006, a member of the committee to hire the new Chancellor at UCR (2008), a member of the All Campus Committee to develop a UC School of Global Health (2006-2010) and on the Board of Director of the Institute of Global Health (2010-2016). She also served as the Chair of the UCR Academic Senate Committee on Diversity and Equal Opportunity and served on the equivalent UC-wide committee. She was appointed to the UCR Chancellor’s Council on Climate, Culture and Inclusion (2010-present). In 2008-2009, she won both the Distinguished Service Award and the Innovative Teaching Award for UCR and in 2010 was elected fellow of AAAS. Member of the Wound Healing Society Board of Directors 2011-2014. Was recently elected to the Board of Director of the Wound Healing Foundation as Vice-President for Research 2017-. Was Chair of the Department of Molecular, Cell and Systems Biology 2017-2021. More recently, she received the UC Oliver Johnson Awards for her leadership accomplishments at the UC wide system (2020), received the Wound Healing Society distinguished service award (2021) for leadership in the Wound Healing Society, was included in “Mulheres na Ciencia” in Portugal (2021) and just received the Chancellor's Award for Excellence in Undergraduate Research and Creative Achievement (2022).

Professor Lewis started his PhD research on polyether sodium channel activator toxins known as ciguatoxins, which are responsible for ciguatera fish poisoning. He then spent 10 years researching the problem at the Queensland Department of Primary Industries before moving back to The University of Queensland in 1995 to initiate research into the phamacology of conotoxins, small venom peptides produced by cone snails. This research led to the development of Xen2174 as a new class of non-competitive norepinephrine transporter inhibitors for the treatment of severe pain at Xenome Ltd, a company he co-founded. Professor Lewis’ current research interests include the origins and detection of ciguatoxins and the elucidation of the evolution and pharmacology of conopeptides, especially the discovery of novel classes of peptides that may be useful for the treatment of pain. Presently he is Professor of Molecular Pharmacology and was inaugural Director of the IMB Centre for Pain Research in the Institute for Molecular Bioscience (IMB) at The University of Queensland, Australia.

Nestoria is a Career Goal-oriented, she has been teaching Higher Education for more than 15+ years in both undergraduate and graduate online/hybrid in Education, Health Care Administration and Public Health Epidemiology Courses. Expert in Community Health Leadership Development, Public Health Program assessment, development, implementation, evaluation, and public health research. Proven expertise in Health Promotion and Education strategic program planning, disease outbreak investigation, public health emergency preparedness and Epidemiologist, disease infection control specialist and public health professional specialist. Diabetes Health Educator, Group Healthy Lifestyles Balance Instructor, Health and wellness educator and Certified Health Education Specialist (CHES) for more than 10 years with the different US Air Force Bases. Formal education includes a Bachelor of Science in Health Services Organization and Policy Minor in Psychology, Bachelors of Science in Education, Master in Education WSU and Master in Public Health Kansas University (KU)Major in Community Health and Leadership Development, Ph.D. in Public Health Major in Epidemiology at Walden University Minneapolis, MN. Currently, she is looking forward to continuing developing and promoting a comprehensive environmental health protection program for the Kickapoo Tribe in Kansas that will protect the natural, cultural, and human health.

Dr. NaoualOukkache leads the Venoms and Toxins Laboratory at the Pasteur Institute of Morocco. Driven by passion, Naoual excels in animal venoms and antivenoms focusing on proteomics, pharmacology, antibody engineering and preclinical studies. She trained and collaborated with several institutes including Marseille University of Medicine, Butantan Institute, Cuernavaca Biotechnology Institute, Kuala Lumpur Monash University; as well as the Atheris and Bioclon companies. Naoul currently participates in clinical studies and develops innovative antivenoms.

Ilya B. Tsyrlov, MD, has completed his PhD in Biochemistry at the agehttps://www.spectrumconferences.com/cms/photos/360-Plenary-Photo.jpg of 27, and thereafter – a higher degree Doctor of Science in Molecular Pharmacology. He has been working as Group leader, Head of the laboratory, and Department chair at Russian Academy of Science. In the United States, Tsyrlov served a Senior Scientist at NCI/NIH, and a Research Professor at Mount Sinai School of Medicine. Since 2005, a President/CSO of the XENOTOX, Inc, USA. Incepted and developed Xenobiotical Virology, an interdisciplinary biomedical field, and also studied site-specific modifications of analgesics, synthetic opioids, and antimalarials thus developing long-acting drug delivery formulations. He is the author of 6 monographs and 300+ peer-reviewed publications, and has been serving as an editorial board member of reputed journals.

Dr. Bram Ramjiawan is the Director of Research, Innovation and Regulatory Affairs and Director of Research, Asper Clinical Research Institute at the St. Boniface Hospital and Research Centre in Winnipeg, Canada. Dr. Ramjiawan is responsible for the Office of Clinical Research which oversees and ensures that all clinical, regulatory and business issues are handled as required by National (Health Canada) and international agencies (EU, FDA). Prior to joining the hospital, Dr. Ramjiawan spent 15 years with the Government of Canada (National Research Council) as an Industrial Technology advisor who specialized in Life Sciences and Biomedical Technologies. Dr. Ramjiawan is a seasoned biomedical researcher that has contributed to the development of numerous biomedical technologies that have either been licensed to Multinational and National Companies or spun-off into stand alone successful Canadian business. Dr. Ramjiawan is an adjunct professor of Pharmacology and Therapeutics in the Max Rady College of Medicine, Faculty of Health Sciences at the University of Manitoba. He is also the co-chair of the St. Boniface Hospital Research Ethics Committee. Dr. Ramjiawan is an active member of many National and International organizations. At the international level, he is a reviewer for numerous bodies including the United States National Institute of Health and for the European Union Commission on Health Science and Ethics. Dr. Ramjiawan is on the editorial board of Numerous Scientific Journals.

Dr. Weiping Shao is currently Sr. Director and Head of US GxP Testing Laboratories at AstraZeneca, where he leads regulated bioanalysis and scientific innovation to support the development of biologics modalities from pre-clinical to clinical across all therapeutic areas. Weiping brings more than 20 years of experience and leadership in pharmaceutical /biotech industry, including his previous role as Vice President and Head of Biologics Services at a global CRO, Director and Head of Bioanalytical Operations at Regeneron Pharmaceuticals, Inc and Research Fellow at Merck. He has built and led cross-functional organizations that support biologics development, bioanalytical services and biomarker discovery. Weiping has published over 40 peer reviewed manuscripts/commentaries, filed US patents and co-authored industry Best Practices. He holds leadership roles at ISBER organization, chairs conferences and has given numerous presentations. He earned his Ph.D. from Nanjing University and completed his post-doctoral Fellowship in Biochemistry at University of California, San Diego.

Carmela Saturnino is a Professor of Medicinal Chemistry at the University of Basilicata. She was the Fellow of the Pharmaceutical Industry Servier in Paris and later in the University of Caen, France. She is the co-author of 112 publications and 6 Patents. Her research interest is in Carbazoles, Metalocines, Pyrazoles, suzuki reaction, design, synthesis and biological studies, and understanding of the mechanisms of action of new therapeutic molecules for cancer, neurodegenerative diseases and antimicrobial agents.

Dr. Sanjay K. Srivastava is a University Distinguished Professor and Chairman of the Department of Immunotherapeutics and Biotechnology, and Associate Dean for Graduate Programs at the Texas Tech University Health Sciences Center. He is also James ‘Buddy’ Davidson Endowed Professor of Pediatric Pharmacology and Oncology. He has extensive research experience in the field of cancer chemoprevention and therapeutics. Dr. Srivastava is a serial innovator with several patents to his credit. His inventive contributions are supported by an excellence in research. Named in Stanford University’s list for the World’s Top 2% Scientists for 2020 & 2021, Dr. Srivastava has a track record of being a productive scientist, authoring more than 160 research articles in high impact journals and holding an H-index of 57, demonstrating just how impactful his research contributions have been over the years. His research has been funded by National Cancer Institute or other agencies, and he has received numerous prestigious awards. The major focus of his laboratory is on delineating the signaling mechanisms responsible for tumor growth, angiogenesis and metastasis in different cancer models including pancreatic, ovarian, breast, melanoma and glioblastoma. His recent research focuses on understanding the mechanism of chemotherapeutic drug resistance in melanoma, breast and glioblastoma. Forthelast10+ years, hehas also beenrepurposingexisting non-cancer drugsforcancertherapy.For example, his group has shown the anticancer effects of few anti-psychotic drugs for breast cancer, brain cancer, and pancreatic cancer therapy. He also showed the anti-tumor effects of anti-malarial and anti-helminthic drugs for drug resistant breast cancer. Dr. Srivastava has mentorednumeroustrainees(undergraduatestudents,post- doctoralfellows andgraduatestudents), whoare nowestablishedresearchers/facultyat different places. His research has been highlighted by media and news agencies.

Donglu Zhang is a Senior Fellow in DMPK at Genentech. He is interested in applying drug metabolism studies in drug design and development of both small molecules and antibody-drug conjugates (ADCs). He received the Sir James Black Award for discovery of and original research on Eliquis from British Pharmacological Society (2018) and the Ondetti and Cushman Award for invention of mass defect filtering method (MDF) from Bristol-Myers Squibb (2007). He is on Editorial Board of Drug Metabolism and Disposition and Xenobiotica. He received his Ph.D. in Organic Chemistry from University of Utah under the direction of C. Dale Poulter.

Elisa Benetti is an Associate Professor in Pharmacology at the Dept. of Drug Science and Technology of the University of Turin. She is a co-author of more than 40 research papers. Her main research field is the study of new pharmacological strategies for the treatment of type 2 diabetes, focusing in particular on insulin resistance and its link with inflammation. She is a member of the European Association for the Study of Diabetes (EASD) and of the Italian Society of Pharmacology (SIF).

Prof. Lucia Grumetto is a Member of “Consorzio inter Universitario I.N.B.B, Istituto Nazionale Biostrutture e Biosistemi (http://www.inbb.it)- National Laboratory of Endocrine Disruptors”. Member of the Editorial Board of "International Journal of Pharma Research and Health Sciences" and of Frontiers in pharmacology Journal, section Translational Pharmacology. Author of more than 70 research papers and speaker at various symposia. Scientific research in the fields of pharmaceutical sciences, mainly on two research topics: development and validation of analytical-pharmaceutical methods for the determination of xenobiotics in complex matrices (food, environmental and biological matrices); Biochromatography: determination of in vitro parameters representative of xenobiotics/biostructures interactions and their correlation with biological activity data. Pharmacokinetic evaluations: transdermal passage assessment of actives set up in topical formulations

Mar Crespo is a pharmacist, MSD in Toxicology, ERT by EUROTOX, with more than fifteen years of successful experience in developing clinical and preclinical reports for the pharmaceutical industry. She is CEO at TOXICONSULTANT S.L. Mar specializes in Occupational Exposure and her background both in clinical and preclinical fields contribute to provide a High-Quality criteria for Risk Assessment . In addition, her knowledge in production areas inside the pharmaceutical industry help her to have a more realistic view of how to incorporate an API in multiproduct facilities under the point of view of safety and hygiene. Currently, she is a student in the Doctoral Program in Life Science at the Universidad de Alcalá de Henares (UAH) writing her thesis in occupational toxicology. She is also a Professor in the International Master in Toxicology (Mastertox) by Ilustre Colégio Oficial de Químicos de Sevilla (Spain) and a Master Tutor in “Toxicologie Humaine Evaluation risques et Vigilance” for the Université Paris-Saclay and Université de Paris.

Ehi has over 20 years’ experience working within academia and the public sector as a Research Scientist, Public Health Scientist and Toxicologist. She worked previously for Public of England (now UK Health Security Agency) where she provided risk assessment and toxicology advice to Government agencies and other stakeholders on the health effects of exposure to chemicals in drinking water, contaminated land, consumer products and waste processes. She is the current leads the toxicology team at the National Centre for Environmental Toxicology (NCET) part of WRc. NCET undertake research into chemical and environmental hazards to underpin policy and carry out assessments to determine the potential chemical or environmental risks associated with exposures to chemicals.

Dr. Yuh-Lien Chen is a University Professor and Chairman of the Institute of Anatomy and Cell Biology in College of Medicine, National Taiwan University. She completed her Ph.D. from Institute of Anatomy, College of Medicine, National Taiwan University.She is the author of more than 100 peer-reviewed publications. The main focus of her laboratory is to investigate the development, related mechanisms and prevention of cardiovascular diseases. The major results are: (1) Isolation, culture and application of stem cells from umbilical cord interstitium or adipose tissue: Our laboratory has successfully isolated stem cells from umbilical cord interstitium or adipose tissue, which can repair damaged skin flaps, reduce cardiac ischemia/reperfusion injury and further explore its related mechanisms. The experimental results show that stem cells isolated and cultured from human adipose tissue and umbilical cord mesenchyme can be used for academic research, and can also be used in future clinical medicine to overcome the problems of tissue deficiency, organ damage, aging, and clinical reconstruction and plastic surgery. (2) To explore the cause of inflammation in cardiovascular disease or respiratory disease: the experimental results clarified that ischemia/reperfusion caused severe damage to cardiomyocytes and programmed cell death. In addition, it is also clarified that suspended particulate matters (PMs) can significantly increase lung epithelial cell inflammation or epithelial-mesenchymal transition both in vivo and in vitro, and explore its mechanism in depth.(3) The role of miR-221/-222 in the inflammatory process and its antioxidant properties: miR-221-222 is closely associated with cell adhesion molecule (ICAM-1), programmed cell death-associated protein (PUMA), and fibrosis-related protein (ETS-1) levels. Wild bitter melon fruit extract has anti-inflammatory and anti-oxidative activities in vitro and in vivo, through the signal transduction pathway of miR-221/-222/PI3K/AKT/NF-κB.

Dr. Sanjay Gupta is a Professor and holds Carter Kissell Endowed Chair in Urologic Oncology in the Department of Urology at Case Western Reserve University and the position of Research Director at the Urology Institute, University Hospitals Cleveland Medical Center. He also holds secondary appointments in the Departments of Pharmacology, Pathology, Nutrition and Division of General Medical Sciences at Case Comprehensive Cancer Center. Dr. Gupta had a joint appointment as Research Scientist from 2015 to 2020 at the Louis Stokes VA Medical Center, Cleveland, Ohio. Dr. Gupta obtained faculty position in 2002 at Case Western Reserve University, School of Medicine.

Prof. Kirsten Benkendorff is the Director of the National Marine Science Centre, Southern Cross University, Australia. She obtained her PhD from the University of Wollongong in 1999, followed by an Australian Research Council Postdoctoral Fellowship, then a lectureship at Flinders University, before moving to Southern Cross University in 2010. Kirsten is an interdisciplinarymarine researcher who applies the tools of chemistry to answer biological questions concerning valuable marine resources. She has made significant contributions towards assessing the impacts of ocean climate change and environmental contaminantson the health, nutritional quality and functional food properties of seafood species. She is also investigating the use of marine molluscs for human medicine and has identified a promising anticancer and anti-inflammatory agent currently in preclinical trials. Kirsten has published over 120 peer-reviewed papers in international scientific journals (H-index = 39). She supports a large team of postgraduate research students and has supervised an international team of 28 PhD, 7 Masters and 33 Honours students to completion.Prior to moving to the National Marine Science Centre, Kirsten was the Director of Higher Degree Research and Training for the School of Science and Engineering.In recognition of her contributions to marine science, Kirsten was awarded the 2000 Young Australian of the Year Award in Science and Technology, a 2008 SA Young Tall Poppy Award and the 2011 Dorothy Hill Award from the Australian Academy of Science.

Will be updated soon...

Laurent Charlet. Distinguished Professor in Bio-nano-geochemistry atISTerre, University Grenoble Alpes (UGA), France, he earned an Engineering degree in France, and a Ph.D.in Soil and Environmental Sciences at the University of California, USA, followed by two postdocs in Switzerland (EAWAG and Uni Bern). He created the Environmental Geochemistry laboratory at ISTerre and brought it into the global spotlight by performing research at drastically different scales: (i) large-scale multidisciplinary field investigations (on the fate of toxins such as mercury in Amazonian forest and arsenic in SE Asian deltas) and (ii) molecular level investigations at synchrotron facilities(µXAFS, ESR, Mössbauer), particularly ESRF, France, with a special focus on toxicology, chemical issues of importance to human health particularly related to redox-active trace elements, as a basis of risk assessment Public Health Policy. He is the holder of the CNRS Silver Medal for Excellence in Research, an Honorary chair at the University of Swansea (UK), an Honorary member of the Institut Universitaire de France, and 10 years long International Research advisor to the UGA Chancellor. He is presently an Affiliate to LBNL, Berkeley (USA) and Adjunct Professor at the University of Waterloo (Canada) and Central Michigan University (USA), and has been visiting professor at UC-Berkeley (US), EPFL-Lausanne (Switzerland), and Uni. Utrecht (The Netherlands).His research was published in 283 primary research publications, cumulating above 11,000 citations and corresponding to an h-index of 77.

Dr. Mauro luisetto university curriculum studiorum in Turin university PHARM D and Pavia university APPLIED PHARMACOLOGIST , Parma university management COURSE -applied pharmacology university specialization, advanced university course clinical pharmacist. European specialist in laboratory medicine , EC4 registered, public hospital pharmacist manager 8 EQF LEVEL Several course in management field (project, strategic, change management, total quality m., knowledge manag. , Healthcare mang.Human resource manag.) Author of many publications in field of: toxicology ,pharmacology , medicinal chemistry pharmaceutical care, clnical pharmacy, pathology Infectious disease , surgery , neuroscience, management , economics. Execution contract DIRECTOR med gas public hospital Italy Antidothes stokes responsible for provincial hospital Editor in chief or editorial board member in many scientific journal. Global clinical pharmacy academy member since 2013 Officially invited in many international scientific congress.

Dr. Wei Wu is an Associate Professor and Associate Department Chair in the Department of Toxicology at Nanjing Medical University, China, where he received his Ph.D. in Toxicology in 2012. He was a guest researcher at the National Institute of Environmental Health Sciences (NIEHS) between 2017 and 2018. He is the PI of State Key Laboratory of Reproductive Medicine and the PI of Key Laboratory of Modern Toxicology of the Ministry of Education. He is a member of different national and international societies in the fields of human reproduction and toxicology, and has received awards from many national societies for the originality and quality of his projects. He has a wide range of teaching and consulting experience, including in the area of toxicology. His research interests include the application of new media technology in teaching, epigenetic mechanisms of transgenerational effects of male infertility induced by endocrine-disrupting chemicals, environmental exposure and male reproductive health, genetic and epigenetic risk factors of male infertility and abnormal fetal growth.

Dr. Gianni Dal Negro is a European Registered Toxicologist with over 30 years of experience in Research and Development applied to both the regulatory and non-regulatory areas in the pharmaceutical sector. In his career, he has been a member of international committees and he has contributed to international initiatives relevant to the 3Rs (science, legislation, regulatory requirements); amongst them, he has represented the European Federation of Pharmaceutical Industries and Associations (EFPIA) in the ECVAM Scientific Advisory Committee (ESAC) and he has served as Industry Chair of the European Partnership for Alternative Approaches to Animal Testing (EPAA). Before retiring, Dr. Dal Negro has covered roles of increasing responsibility at GlaxoSmithKline Ltd in UK, such as Head of Cellular and Biochemical Pathology, Head of Investigative Toxicology, World-wide Director of 3Rs, and Director of Complex In Vitro Platforms. Dr. Dal Negro has authored and co-authored several papers in peer-reviewed journals. He is currently a member of the Editorial Board of the Journal Toxicology In Vitro (Elsevier) and member of the EUROTOX Registration Committee.

Ana Sabater studied IT at the University of Barcerlona, Spain in 1997. She has a Maser degree in Marketing from the Universitat of Barcelona. She has been for the past 20 years involved in the IT business related to the health care. The last 12 years, her role has been to develop and put to the market pharmacogenetics and the unique methodology for a clinical approach of pharmacogenetics on the bed side using g-Nomic personalized prescription and interpretation software to correctly apply pharmacogenetics. She has given more than 30 international presentations about pharmacogenetics and its practical applications.

Lola Llobat (PhD) graduated in biology with a Master of Animal Breeding and Genetics, Master of Sciences, and Doctorate in Animal Genetics. Her research activity began in 2003 carrying out research work in the field of molecular biology related to human disease as HIV, diabetes, oncology, and inflammatory diseases. She is professor of Genetics in Universidad Cardenal Herrera CEU, and expert evaluator for European Union. Currently, she has a total of six research projects, and more than 30 publications and she is the principal investigator of MMOPS research group. The main current research line focuses on the study of the molecular mechanisms of Leishmania infection and the possible genetic resistance to infection. Other lines in research groups are the study of molecular mechanisms of different pathologies, including genetic diseases.

In 2016, Mrs. Asst. Univ. Ana Maria Vlăsceanu. Pharm., PhD started working as an assistant professor at the University of Medicine and Pharmacy of Bucharest's Department of Toxicology. Between 2014 and 2015, she was a PhD student with a scholarship within the Excelis Project (Excellence in scientific, interdisciplinary, doctoral, and postdoctoral research, in the economic, social and medical fields - Excelis, POSDRU/159/1.5/S/138907) (scholarship obtained through competition, project completion in first place). In 2015, she graduated with a master's degree in pharmacology and toxicology from the University of Medicine and Pharmacy in Craiova, Faculty of Pharmacy (grade 10), dissertation: "The influence of the constituents of cigarette smoke on the metabolism of some xenobiotics". She became a specialist pharmacist in the Pharmaceutical Laboratory specialty following training courses through residency in the period 2016-2019 and passing the exam in the September 2019 session. She obtained the scientific title of PhD in the field of Pharmacy, specialty Toxicology, defending, in 2019, the doctoral thesis, appreciated with the Suma cum laude distinction. The didactic activity consists of the guidance of practical works and the assessment of students from the IV and V study years, the guidance of bachelor's works. The scientific and research activity of Mrs. Asst. Univ. Ana Maria Vlăsceanu. Pharm., PhD includes 3 book chapters published as a co-author in international publishing houses, a book/study aid for students, published as a co-author in a national publishing house recognized CNCSIS, 11 published works (of which 8 in ISI rated/indexed journals), 5 papers presented at international scientific events, published as abstract in ISI indexed journals, 3 papers presented at other scientific events. Mrs. Asst. Univ. Ana Maria Vlăsceanu. Pharm., PhD attended a series of specialization courses in Toxicology and Pharmacy (European Society of Toxicology in Vitro, ESTIV, Applied In Vitro Toxicology Course, April 14-19, 2019, Bucharest; "Currents in medico-legal toxicology", Murighiol, May 25, 2017, course held by the board members of The International Association of Forensic Toxicologists, TIAFT, within CNML 2017; "Multidisciplinary pharmacotherapeutic approach"). The preoccupation for the scientific activity is also supported by the two editions of the National Congress of Toxicology, with international participation (Bucharest, Romania 2015 and 2017), that Mrs. Asst. Univ. Ana Maria Vlăsceanu Pharm., PhD contributed as President of the Organizing committee. The research carried out in the scientific activity focused on areas such as pharmacotoxicological testing methods (experimental models for testing the action and toxicity of some medicinal or toxic substances), Food Safety, spectrofluorimetric studies on cell suspensions, following changes in some cellular parameters, addiction (analytical diagnosis, optimization), Ecotoxicology.

Ariane Cofré Espinoza is a young scientist who has devoted her academic and professional career to the field of toxicology. She earned her undergraduate degree in Chemistry at Freie Universität Berlin and decided to change for her master’s degree to Toxicology at Potsdam. Throughout her studies, the focus was on the area of food toxicology, contaminants, and analytics. Since June 2021, Mrs. Cofré has been working at Bilacon, where she specializes in the toxicological and regulatory assessment of contaminants in foodstuffs. Her work is focused on ensuring that food products are safe for consumption by assessing the analyzed levels of various contaminants, including heavy metals, pesticides, and other natural and man-made contaminants.

Dr Mitidieri completed her PhD in "Drug Science" from the University of Naples "Federico II" (Naples,Italy) in 2009. She got part of her postdoctoral studies from William Harvey Research Institute (London,UK) and part from the University of Naples "Federico II" (Naples,Italy). From December 2016 to date she is attending the Department of Pharmacy, University of Naples “Federico II” as Assistant Professor.Her research activity is focused on studying gasotransmitters, nitric oxide, and hydrogen sulfide, in a healthy state and inflammatory vascular disorders. She is also interested in the study of physiopathology in the urogenitourinary tract. More recently, she has been involved in research projects on innovative delivery systems for small drugs and biotech products.

Will be updated soon...

Milena Veskovic was born in 1987. In Leskovac, Serbia. She is employed as an Assistant Professor at the Institute of Pathophysiology, Faculty of Medicine University of Belgrade in Serbia. She has 10 years of experience in academic career. Milena Veskovic has finished her PhD thesis in 2019 in the area of Physiological and Pharmaceutical Sciences through international supervision of doctoral thesis „Cotutelle“, by collaboration with Antwerp University, Belgium, which was the first International doctorate at Faculty of Medicine. She has an expertise in hepatology research that include non-alcoholic and alcoholic fatty liver disease, liver fibrosis and metabolic syndrome. Additionally, she is recently widening the research area towards neurophysiology, including circadian misalignment, mood and behavioral disorders. Milena Veskovic has an experience in international collaboration through the bilateral project related to neurological disorders financed by The Ministry of Science and Technological Development of the Republic of Serbia and The Scientific and Technological Research Council of Turkey. Dr Veskovic is an author in 21 publications indexed in JCR list with 350 citation and Hirsch index 11.

Dusan Mladenovic was born in 1980 in Belgrade, Serbia. He is employed as an Associate Professor at the Institute of Pathophysiology, Faculty of Medicine, University of Belgrade. He has completed his PhD thesis in 2014. in the area of Molecular Medicine. His areas of research include neurophysiology and epileptology and he was involved in translational studies in rat models of chemically-induced seizures and hepatic encephalopathy in the Laboratory for Neurophysiology, Institute of Medical Physiology, Faculty of Medicine in Belgrade. Additionally, he is involved in the research of the effect of circadian misalignment on diabetic complications. Dusan Mladenovic has an experience in international collaboration through the bilateral project related to brain disorders induced by an environmental pollutant lindane financed by The Ministry of Science and Technological Development of the Republic of Serbia and The Scientific and Technological Research Council of Turkey. In 2016 and 2017 he spent 10 months at Philipps University of Marburg, Germany, supported by the DAAD (Deutscher Akademischer Austauschdienst) Research Grant for Doctoral Candidates and Young Academics and Scientists. He is an author of 50 articles indexed in JCR list with 651 citations and Hirsch index 14. For his scientific work he was awarded the best young scientist at the Faculty of Medicine, University of Belgrade in 2018. He was also a supervisor of the first international joint PhD thesis at the Faculty of Medicine, realized in a collaboration between University of Antwerp and University of Belgrade.

Dr. Shankar received is MSc from Department of Biochemistry, Annamalai University, Tamil Nadu India and completed his Ph.D. from Cochin University of Science and Technology, Kerala, India in Neuroscience, from the Department of Biotechnology. He was a post-doctoral research associate in the Department of Molecular Biology and Immunology, University of North Texas Health Science Center, Fort Worth, Texas, USA. He was invited by Dr. Sanjay Gupta, Director of Research, Department of Urology, School of Medicine, Case Western Reserve University, Cleveland Ohio to work in drug repurposing and Chemoprevention. Since 2021 Dr. Shankar is an Assistant Research Professor at the The Ohio State University Comprehensive Cancer Center, Columbus, OH. Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH.The research focus of Dr. Shankar is on breast and prostate cancer studying the molecular mechanism attributing to initiation and metastasis identifying targets associated with cancer progression and drug resistance. Over the last 14 years Dr.Shankar’s research has evolved in elucidating the mechanisms of oncogenes that orchestrate tumor promotion. In the recent years Dr. Shankar has been involved research to repurpose drugs and come out with combinatorial treatments that synergistically inhibit the growth of metastatic breast cancer. In the current position Dr. Shankar in collaboration with Dr. Bhuvaneswari Ramasamy, MD, Breast Oncologist, Ohio State University’s Wexner Medical Center and Dr. Vish Subramaniam, Ph.D. Academy Professor, Department of Mechanical & Aerospace Engineering, and OSU Emeritus Academy is developing combinational treatments to inhibit metastasis withminimal or no toxicity to normal cells. He is also involved in applying induced electricfield (iEF) technology as a non-pharmacological means of treating metastatic cancer. Asevident from his research publications Dr. Shankar has made significant contribution in understanding the molecular signatures altered during this devastating disease. He is funded by the department of defense (DoD)to evaluate the combinatorial effect of dopamine D1 agonist and EZH2 inhibitor GSK126 in arresting triple negative breast cancer progression.

Dan has been working in the MS industry for over 20 years as an instrument and applications specialist and is now responsible for developing the food, environmental and forensic markets throughout the EMEAI region. He has worked with major research and regulatory organisations to develop new applications in line with legislation, traditionally in the area of contaminant analysis. Recent changes in the requirements imposed on and the challenges facing laboratories are constantly evolving, and Dan’s role is now primarily to ensure Sciex produce relevant solutions and to promote them in the industry.

Verónica has a Degree in Biochemistry, Master in Bioengineering (Applied Toxicology and Pharmacology) and PhD in Cellular and Molecular Biology (2017). She started with toxicology research on endocrine disruptors in the Department of Applied Biology at Miguel Hernandez University (UMH) and the Institute of Environmental Medicine at Karolinska Institutet in Stockholm. She began her specialization in ion channels pharmacology as researcher in R&D projects at the Institute of Molecular and Cell Biology (IBMC) of the UMH, now known as IDiBE, in collaboration with the company Lipotec-Diverdrugs, gaining extensive experience in high-throughput toxicological and pharmacogenomic screening for the development of new active compounds in the cosmetic and dermopharmaceutical field. She developed her PhD thesis based on the implementation of a new automated electrophysiology technique for high-throughput screening and drug discovery funded by the Dravet Syndrome Foundation (Spanish Delegation) in the thesis project "Pharmacogenomic screening for Dravet Syndrome". After, she has played for 4 years the role of project leader at Antalgenics S.L focusing on the identification of new targets and techniques for in vitro drug discovery and preclinical studies of candidates for use in sensorial neurobiology and skin pathologies. She is currently working in the Sensorial Neurobiology group of IDiBE, involved in a project to generate a preclinical in vitro human skin model innervated by sensory neurons using tissue engineering and 3D bioprinting.

Dr. Mauro Luisetto, obtained his Pharm D in 1995 from the Turin University and worked as European specialist in laboratory medicine. Currently, he works as Public Hospital Pharmacist Manager and is responsible of hospital medicinal gas quality control PC HOSP. He is also the Director of hospital medicinal gases contract implementation. His working filed and rotation is biochemistry, toxicology, blood bank, haematology. microbiology; hospital pharmacy (drugs logistic, galenic, medicinal gas quality controller , radio drugs, rx contrast agents, departmental pharmacist); clinical pathology, antidothes responsible stokes provincial PC, logistic of diagnostic in vitro), responsible for emergency drug hospital stokes. I was member of ANCT in Rome chemists pharmacists Italian association. I was regional responsible for SINAFO hosp. pharmacists organization (EMILIA ROMAGNA).I am registered as pharmacists in professional order Piacenza Visiting professor at Saint George school italy( pharmacology) form 2016 In my actually job. I have the objective: pharmaceutical care in medical team and involved in clinical pharmacy Antidothes stokes management Medicinal gas quality control as hospital pharmacist. His research interest includes Management, professional social media, ICT, pathology, clinical biochemistry, toxicology, microbiology, imaging, clinical pharmacy, medicinal chemistry, clinical pharmacology, pharmacoeconomy, new professional social media, biomedical database, EBM, Risk management and several other.

Will be updated soon...

Gayatri Mirajkar (Senior Member, IEEE) received the Bachelor of Engineering degree in Electronics Engineering from Karmaveer Bhaurao Patil College of Engineering, Satara, India, the Master of Technology in Electronics and Telecommunication Engineering from Dr Babasaheb Ambedkar Technological University, Lonere, India, in 2005, and the PhD degree in Electronics Engineering from Shivaji University, Kolhapur, India in 2014. She has published several papers in journals and conferences. She has presented her research contributions at IEEE International Conferences in Greece, Hong Kong. She is currently working as Professor in the Electronics and Telecommunication Engineering department of Arvind Gavali College of Engineering, Satara, India. Her research interests include biomedical image analysis, signal denoising, biometrics, cognition, restoration techniques.

I am a Chemical Engineer and Mechanical Engineering double degree and made masters on Environmental Eng. Waste water Recycle topics. Have been in market for 26 years , 14 years in Chemical &Mechanical Sectors lately last 12 years in audits ,training, projects in waste water RECYCLE and ZDHC trainings for Zero Discharge of Hazardous Chemicals to environment to keep away from toxicological trouble for flora and fauna, First Environmental and Chemical Toxicology auditor for INDITEX(ZaraGroup) on world and also approved auditor for 105 brands among HIGG FEM verifier section from america

Sanyukta has two years of experience working as a toxicologist. As an associate scientist at Colgate-Palmolive , she assisted the Global product safety team and toxicologists on special consumer safety projects. As the first-level GPS reviewer she has reviewed clinical and human use protocols, site recipes for all the business's new formulations in the personal care, oral care and home care product range. Now, Sanyukta is working as a toxicologist within the NCET team in WRc, where she performs human health and environmental risk assessment of various chemicals and advise the UK based water companies on the toxicity and health implications of contaminants in drinking water.

Dr. Vikram Gota completed his MD in pharmacology from Christian Medical College, Vellore, following which he briefly worked as a Clinical Investigator in BA/BE studies. Thereafter, he joined the INDO-Oxford (INDOX) Cancer Trials Network at Tata Memorial Centre, Mumbai, where he received training in the design and conduct of phase I clinical trials. During this time he also obtained the post graduate diploma in clinical trials from the London School of Hygiene and Tropical Medicine, University of London. He is presently the officer-in-charge of the department of clinical pharmacology at the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre. His research interests include early clinical development and pharmacokinetics driven optimization of drugs used in cancer. He is involved with the geriatric clinic at TMH since 2019 focusing on rational therapeutics, potentially inappropriate medications and drug-drug interactions, among other things. Hehas worked as an investigator in several phase I clinical trials including first-in-human studies of investigational new drugs.

Chuck Powley is the Chief Scientist at the Center for PFAS Solutions, which is a research lab focused on analysis and remediation of PFAS in drinking water and the environment. He is an analytical chemist with over 35 years of experience in the development and application of analytical methods for trace determination of environmental pollutants and pesticides in water, soil, plants and animal materials. He has published numerous methods in peer-reviewed journals that have become the basis for regulatory and commercial environmentalmonitoring. He obtained a Ph.D. in analytical chemistry from the University of Illinois followed by postdoctoral research at the University of Georgia.

Dr. Seyed Soheil Saeedi Saravi, PharmD, PhD, Co-group Leader and senior scientist at University of Zurich and formerly at Harvard Medical School, received his PhD in 2016 from Tehran University of Medical Sciences (TUMS), followed by a post doc at Harvard Medical School. His research areas include cardiovascular aging, atherosclerosis, and redox biology. He has authored or co-authored over 60 peer-reviewed publications, edited 8 books and chapters, and presented at over 30 international conferences. He has served as editorial board and reviewer of >20 prestigious journals e.g. European Heart Journal, and professional member of over 10 international scientific associations, including American Heart Association (AHA), European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). He has been honored with numerous international and national awards (25 prizes), namely, including "Paul Dudley White International Award" from American Heart Association, "AGLA Walter Riesen Award" from Swiss Atherosclerosis Association, "European Atherosclerosis Society Young Investigator Fellowships 2021 & 2022", and "Harvard Postdoctoral Fellowship".